Physician profile
Prabha Mohan
NPI 1548362098
$1,658.82
in general payments reported to CMS, 2019-2025
24 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $175 · 2021: $312 · 2022: $218 · 2023: $478 · 2024: $191 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $245.38 | 2019-2023 | |
| Abbvie INC. | $193.37 | 2021-2025 | |
| Novo Nordisk INC | $190.43 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Idorsia Pharmaceuticals US INC | $113.18 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $95.67 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $95.29 | 2021 | |
| Boston Scientific Corporation | $93.83 | 2023 | Watchman Access System |
| Abbott Laboratories | $88.02 | 2021-2023 | Freestyle Libre 3 |
| Amgen INC. | $57.86 | 2019-2025 | Evenity, Prolia |
| Lilly USA, LLC | $54.15 | 2023-2024 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $53.28 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $49.02 | 2024 | Voquezna |
| Athena Bioscience, LLC | $39.76 | 2022-2024 | Nexiclon Xr |
| Sunovion Pharmaceuticals INC. | $36.11 | 2021-2022 | |
| Exact Sciences Corporation | $36.01 | 2023 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $34.29 | 2020-2021 | |
| Glaxosmithkline, LLC. | $33.96 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $31.41 | 2021-2024 | Dexcom G6 Transmitter |
| Vertex Pharmaceuticals Incorporated | $29.92 | 2025 | |
| Xeris Pharmaceuticals, INC. | $27.20 | 2023-2024 | Keveyis |
| Sanofi-Aventis U.S. LLC | $16.74 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.39 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.87 | 2022 | |
| Linus Health, INC. | $13.68 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prabha Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.